江苏恒瑞医药股份有限公司第九届董事会第二十二次会议决议公告

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has approved two significant related-party transactions involving the signing of an exclusive licensing agreement and a commercialization service framework agreement with Hansoh Pharmaceutical Group Co., Ltd. [1][2][7] Group 1: Transaction Overview - The company has signed an exclusive licensing agreement to grant Hansoh Pharmaceutical the rights to develop, produce, and commercialize the SHR6508 project in mainland China [8][10] - The SHR6508 project is a novel calcium-sensing receptor modulator intended for treating secondary hyperparathyroidism in chronic kidney disease patients undergoing dialysis, currently in Phase III clinical trials [9][31] - The company’s subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd., has entered into a commercialization service framework agreement with Hansoh's subsidiary, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., to provide non-exclusive commercialization services for the product Paricalcitol soft capsules [11][12] Group 2: Financial Terms - Under the exclusive licensing agreement, Hansoh Pharmaceutical will pay an upfront fee of RMB 30 million, with potential milestone payments up to RMB 190 million based on regulatory and commercialization achievements, and a sales commission of up to 9% based on quarterly net sales [13][29] - The commercialization service framework agreement will involve service fees based on the actual net sales of the product, with specific rates to be determined in future agreements [26][28] Group 3: Strategic Rationale - The licensing agreement allows the company to focus resources on priority therapeutic areas while leveraging Hansoh Pharmaceutical's expertise and established network in the relevant treatment fields [31][32] - The commercialization service agreement is expected to expedite market entry and reduce costs associated with building an internal sales team, thus optimizing capital allocation [33]